BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America. It offers BLIS K12, an oral probiotic that supports ear, nose, and throat health, as well as immunity and bad breath; BLIS M18, an oral probiotic for teeth and gums health; and BLIS Q24, a probiotic that balances the skin microbiome and restores skin's health. The company's products are used in various health areas, including ear, nose, throat, immune, dental, and skin, as well as pet oral. It exports its products. The company was formerly known as Tarn Holdings Limited and changed its name to BLIS Technologies Limited in August 2000. BLIS Technologies Limited was incorporated in 2000 and is headquartered in Dunedin, New Zealand.
Часто задаваемые вопросы
В каком секторе работает BLIS Technologies Limited (BLT)?
BLIS Technologies Limited относится к сектору Здравоохранение.
Какова текущая цена акций BLIS Technologies Limited (BLT)?
По последним данным, цена акций BLIS Technologies Limited составляет 0,03 NZ$, предыдущее закрытие — 0,03 NZ$.
Выплачивает ли BLIS Technologies Limited (BLT) дивиденды?
Нет, BLIS Technologies Limited не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у BLIS Technologies Limited (BLT)?
У компании BLIS Technologies Limited бета 0.644, что указывает на более низкую волатильность по сравнению с рынком в целом.
